6 Mar 2015 07:00
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Directorate Change
Lifeline Scientific (AIM: LSIC), the transplantation technology company, announces that Dr. Steven Mayer, a Non-Executive Director, has decided not to stand for re-election at the Company's annual general meeting in June 2015 in order to devote more time to demands of other business endeavours, and therefore Dr. Mayer will no longer be a director of the Company from that time.
John Garcia, Chairman of Lifeline, commented: "We would like to thank Dr. Mayer for his valuable contributions to the Company over the last twelve years and wish him well for the future."
For further information:
Lifeline Scientific, Inc. | www.lifeline-scientific.com |
David Kravitz, CEO | Tel: +1 847 294 0300 |
Lisa Kieres, CFO | Tel: +1 847 294 0300 |
Panmure Gordon (UK) Limited | Tel: +44 (0)20 7886 2500 |
Freddy Crossley (Corporate Finance) | |
Maisie Atkinson (Corporate Broking) | |
Walbrook | Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com |
Paul McManus | Mob: +44 (0)7980 541 893 |
Mike Wort | Mob: +44 (0)7900 608 002 |
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product, LifePort Kidney Transporter, is the global market-leading medical device for hypothermic machine preservation of donor kidneys. LifePorts and novel solutions designed for preservation of other organs are in development, with LifePort Liver Transporter next in line for commercial launch. For more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to help improve kidney preservation, evaluation and transport prior to transplantation. It has been widely studied in clinical trials throughout the world and is the standard of care for machine preservation of kidneys. Employed by surgeons in over 185 leading transplant programmes in 27 countries, LifePorts have successfully preserved over 47,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modeled upon the clinically proven technology platform of LifePort Kidney Transporter and the Company's early HMP prototype successfully used in clinical transplant studies by surgeons at New York-Presbyterian Hospital/Columbia University Medical Center. LifePort Liver Transporter and the Company's proprietary machine preservation solution, Vasosol®, are in the process of US and European regulatory registrations. The system is designed to help improve outcomes in liver transplantation by enabling the clinical use of hypothermic machine perfusion, and has been developed in consultation with clinical and research teams specializing in liver transplantation at Columbia University Medical Center and the University of Chicago. The system employs a rugged, streamlined ergonomic design for ease of use and transportability from donor bedside to recipient operating room. For more information please visit: http://www.organ-recovery.com/pipeline.php